Jan Gossen is a molecular biologist by training and has obtained his PhD at Leiden University in 1993.
He subsequently moved to Ingeny BV where he was the Head of the Transgenic animal department and successful in commercializing a transgenic mouse model he developed during his PhD training (Mutatmmouse). In 1992 he moved to Harvard Medical School (Beth Israel Hospital) as a research Instructor in aging research.
From 1994 to 2011 he has been at Organon/MSD where he has held several positions. He has been responsible for all osteoporosis research for projects from early target discovery up to Phase 2 clinical studies. During 2011-2012 he has been Therapeutic Area Head Oncology (ad interim) at Amgen BV where he was involved in the market introduction of Xgeva for treatment of osteoporosis and bone cancer. He has been a consultant for various Life Sciences companies until the start of Osteo-Pharma on March 1, 2015.